These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11119512)

  • 1. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection.
    Gicheru MM; Olobo JO; Anjili CO; Orago AS; Modabber F; Scott P
    Infect Immun; 2001 Jan; 69(1):245-51. PubMed ID: 11119512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
    Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG
    Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
    Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
    Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
    Coler RN; Skeiky YA; Bernards K; Greeson K; Carter D; Cornellison CD; Modabber F; Campos-Neto A; Reed SG
    Infect Immun; 2002 Aug; 70(8):4215-25. PubMed ID: 12117930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen.
    Masina S; M Gicheru M; Demotz SO; Fasel NJ
    J Infect Dis; 2003 Oct; 188(8):1250-7. PubMed ID: 14551897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
    Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
    J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
    Afonso LC; Scharton TM; Vieira LQ; Wysocka M; Trinchieri G; Scott P
    Science; 1994 Jan; 263(5144):235-7. PubMed ID: 7904381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK; Titus RG
    Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.
    Cote-Sierra J; Bredan A; Toldos CM; Stijlemans B; Brys L; Cornelis P; Segovia M; de Baetselier P; Revets H
    Infect Immun; 2002 Jan; 70(1):240-8. PubMed ID: 11748189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated inoculation of killed Leishmania major induces durable immune response that protects mice against virulent challenge.
    Okwor I; Kuriakose S; Uzonna J
    Vaccine; 2010 Jul; 28(33):5451-7. PubMed ID: 20558242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.
    Soto M; Corvo L; Garde E; Ramírez L; Iniesta V; Bonay P; Gómez-Nieto C; González VM; Martín ME; Alonso C; Coelho EA; Barral A; Barral-Netto M; Iborra S
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003751. PubMed ID: 25955652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease.
    Amaral VF; Teva A; Oliveira-Neto MP; Silva AJ; Pereira MS; Cupolillo E; Porrozzi R; Coutinho SG; Pirmez C; Beverley SM; Grimaldi G
    Mem Inst Oswaldo Cruz; 2002 Oct; 97(7):1041-8. PubMed ID: 12471434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.
    Rhee EG; Mendez S; Shah JA; Wu CY; Kirman JR; Turon TN; Davey DF; Davis H; Klinman DM; Coler RN; Sacks DL; Seder RA
    J Exp Med; 2002 Jun; 195(12):1565-73. PubMed ID: 12070284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice.
    Doroud D; Zahedifard F; Vatanara A; Najafabadi AR; Rafati S
    Parasite Immunol; 2011 Jun; 33(6):335-48. PubMed ID: 21410716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
    J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.